Literature DB >> 26960721

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Oliver A Cornely, Rafael F Duarte, Shariq Haider, Pranatharthi Chandrasekar, David Helfgott, Javier López Jiménez, Anna Candoni, Issam Raad, Michel Laverdiere, Amelia Langston, Nicholas Kartsonis, Marlou Van Iersel, Nancy Connelly, Hetty Waskin.   

Abstract

Entities:  

Year:  2016        PMID： 26960721      PMCID： PMC7297299          DOI： 10.1093/jac/dkw079

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
In the key for Figure 2, the labelling of the curves should be reversed so that the black curve is labelled ‘300 mg (HSCT)’ and the grey curve is labelled ‘300 mg (AML/MDS)’. The authors apologize for this error.
  5 in total

1.  Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.

Authors:  A Petitcollin; C Boglione-Kerrien; C Tron; S Nimubona; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.

Authors:  Pier Giorgio Cojutti; Anna Candoni; Davide Lazzarotto; Nicholas Rabassi; Renato Fanin; William Hope; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-08-19       Impact factor: 4.335

3.  Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis; Pierluigi Viale; Eric M Sarpong
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

Review 4.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

5.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.